Form 4: Halozyme Therapeutics CEO Sells Shares
Insider Transaction (Form 4)
Helen Torley, PRESIDENT AND CEO and a Director of Halozyme Therapeutics, Inc., sold 60,000 shares of common stock on September 9, 2026.
Summary
- Option exercise/conversion: acquired 20,000 Common Stock at $18.41 ($368,200) on September 9, 2026; holds 787,780 after (Direct).
- Open-market sale: disposed of 13,304 Common Stock at $107.22 ($1,426,481) on September 9, 2026; holds 774,476 after (Direct).
- Open-market sale: disposed of 6,596 Common Stock at $107.82 ($711,187) on September 9, 2026; holds 767,880 after (Direct).
- Open-market sale: disposed of 100 Common Stock at $108.67 ($10,867) on September 9, 2026; holds 767,780 after (Direct).
- Option exercise/conversion: acquired 20,000 Common Stock at $18.41 ($368,200) on September 10, 2026; holds 787,780 after (Direct).
- Open-market sale: disposed of 14,588 Common Stock at $107.01 ($1,561,091) on September 10, 2026; holds 773,192 after (Direct).
- Open-market sale: disposed of 5,412 Common Stock at $107.58 ($582,228) on September 10, 2026; holds 767,780 after (Direct).
- Option exercise/conversion: acquired 20,000 Common Stock at $18.41 ($368,200) on September 11, 2026; holds 787,780 after (Direct).
- Open-market sale: disposed of 15,492 Common Stock at $107.15 ($1,660,030) on September 11, 2026; holds 772,288 after (Direct).
- Open-market sale: disposed of 4,508 Common Stock at $107.55 ($484,826) on September 11, 2026; holds 767,780 after (Direct).
- Option exercise/conversion: disposed of 20,000 Option to Purchase Common Stock at $18.41 ($368,200) on September 9, 2026; holds 121,552 after (Direct).
- Option exercise/conversion: disposed of 20,000 Option to Purchase Common Stock at $18.41 ($368,200) on September 10, 2026; holds 101,552 after (Direct).
- Option exercise/conversion: disposed of 20,000 Option to Purchase Common Stock at $18.41 ($368,200) on September 11, 2026; holds 81,552 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $6,436,711 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Helen Torley — Director, Officer (PRESIDENT AND CEO)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-09 | Option exercise/conversion | Common Stock | 20,000 | $18 | $368.2K | 787,780 |
| 2026-09-09 | Open-market sale | Common Stock | 13,304 | $107 | $1.4M | 774,476 |
| 2026-09-09 | Open-market sale | Common Stock | 6,596 | $108 | $711.2K | 767,880 |
| 2026-09-09 | Open-market sale | Common Stock | 100 | $109 | $10.9K | 767,780 |
| 2026-09-10 | Option exercise/conversion | Common Stock | 20,000 | $18 | $368.2K | 787,780 |
| 2026-09-10 | Open-market sale | Common Stock | 14,588 | $107 | $1.6M | 773,192 |
| 2026-09-10 | Open-market sale | Common Stock | 5,412 | $108 | $582.2K | 767,780 |
| 2026-09-11 | Option exercise/conversion | Common Stock | 20,000 | $18 | $368.2K | 787,780 |
| 2026-09-11 | Open-market sale | Common Stock | 15,492 | $107 | $1.7M | 772,288 |
| 2026-09-11 | Open-market sale | Common Stock | 4,508 | $108 | $484.8K | 767,780 |
| 2026-09-09 | Option exercise/conversion | Option to Purchase Common Stock | 20,000 | $18 | $368.2K | 121,552 |
| 2026-09-10 | Option exercise/conversion | Option to Purchase Common Stock | 20,000 | $18 | $368.2K | 101,552 |
| 2026-09-11 | Option exercise/conversion | Option to Purchase Common Stock | 20,000 | $18 | $368.2K | 81,552 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-09 | Option exercise/conversion (20,000 shares) |
| 2026-09-09 | Open-market sale (13,304 shares) |
| 2026-09-09 | Open-market sale (6,596 shares) |
| 2026-09-09 | Open-market sale (100 shares) |
| 2026-09-10 | Option exercise/conversion (20,000 shares) |
| 2026-09-10 | Open-market sale (14,588 shares) |
| 2026-09-10 | Open-market sale (5,412 shares) |
| 2026-09-11 | Option exercise/conversion (20,000 shares) |
| 2026-09-11 | Open-market sale (15,492 shares) |
| 2026-09-11 | Open-market sale (4,508 shares) |
| 2026-09-09 | Option exercise/conversion (20,000 shares) |
| 2026-09-10 | Option exercise/conversion (20,000 shares) |
| 2026-09-11 | Option exercise/conversion (20,000 shares) |
Keywords
insider transaction, Form 4, HALO, HALOZYME THERAPEUTICS, INC., bearish, Helen Torley
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.